AMA1-C1/Alhydrogel + CpG 7909 for Malaria

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Plasmodium Falciparum Malaria
Interventions
BIOLOGICAL

AMA1-C1/Alhydrogel®

AMA1-C1/Alhydrogel malaria vaccine, cloudy suspension, 0.5 mL dose containing up to equivalent of 377 mcg of aluminum as Alhydrogel® (800 mcg of aluminum hydroxide gel per dose) onto which 20 mcg or 80 mcg of recombinant AMA1-C1 is bound. Dosages: 20 mcg and 80 mcg administered via the deltoid muscle by IM injection

BIOLOGICAL

CPG 7909 Oligodeoxynucleotide (VaxImmune®)

CPG 7909 is an investigational agent and is supplied in sterile vials at 10mg/mL in phosphate buffered saline for intramuscular administration. Dosage 500 mcg.

Trial Locations (1)

14642

University of Rochester, Rochester

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00344539 - AMA1-C1/Alhydrogel + CpG 7909 for Malaria | Biotech Hunter | Biotech Hunter